Regeneron, Vyriad sign deal to develop oncolytic virus-based treatments

This article was originally published here

Both firms will also sign a five-year research agreement to use Regeneron’s VelociSuite technologies to jointly design and validate Vesicular Stomatitis Virus (VSV)-based oncolytic virus treatments. Under the

The post Regeneron, Vyriad sign deal to develop oncolytic virus-based treatments appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply